This protein carries no "tag". The protein has a calculated MW of 19 kDa (monomer). As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).
VEGF
Origine: Porc
Hôte: Escherichia coli (E. coli)
Recombinant
> 95 % as determined by reducing SDS-PAGE.
Restrictions
For Research Use only
Format
Lyophilized
Buffer
PBS, pH 7.4
Conseil sur la manipulation
Please avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
Stumpf, Wimmer, Lorenz, Stieger: "Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF." dans: PLoS ONE, Vol. 15, Issue 3, pp. e0230344, (2020) (PubMed).
Chen, Hsueh, Lee, Tsai, Tsai, Chiang: "FGF primes angioblast formation by inducing ETV2 and LMO2 via FGFR1/BRAF/MEK/ERK." dans: Cellular and molecular life sciences : CMLS, (2020) (PubMed).
Keys, Wetter, Hang, Rutschmann, Russo, Mally, Steffen, Zuppiger, Müller, Schneider, Faridmoayer, Lin, Aebi: "A biosynthetic route for polysialylating proteins in Escherichia coli." dans: Metabolic engineering, Vol. 44, pp. 293-301, (2018) (PubMed).
VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.